Watch time: 2 minutes
“In the future, it would be nice if even non-carriers could join, but as far as selection is concerned, [patients] Adequate levels of amyloid and tau pathology should also respond to ALZ-801. ”
ALZ-801 (Alzheon), an oral anti-amyloid agent, is an optimized prodrug of tramiprosate that has been shown to inhibit the aggregation of amyloid-β (Aβ)42 into toxic oligomers. This treatment is based on the apolipoprotein (appointment) ε4/4 or ε3/4 genotype. Of her 75 participants who completed 52 weeks of treatment, the ALZ-801-treated patient had a significant 41% decrease in plasma phosphorylated tau 181 (p-tau181) from baseline his showed (P. = .016). In addition, the drug also significantly reduced the plasma p-tau181/Aβ42 ratio by 37% at the same time point (P. = .032).
These findings were originally presented in September 2022 and were further discussed at the 2022 Alzheimer’s Disease Clinical Trials (CTAD) Conference November 29-December 2 in San Francisco, CA. ALZ-801, a potential disease-modifying therapy, is currently being evaluated in a Phase 3 trial called APOLLOE4 (NCT04770220) with the help of his $47 million grant from the National Institute on Aging. . This 78-week study will evaluate the efficacy, safety, biomarkers, and imaging effects of ALZ-801 265 mg orally twice daily. appointment The ε4/4 genotype constitutes approximately 15% of the AD population.
At CTAD 2022, neurology live® has caught up with Susan Abushakra, MD, Chief Medical Officer of Alzheon and Principal Investigator of the ALZ-801 clinical program. Abushakra provided insight on next steps for ALZ-801. This includes ongoing phase 3 trials and other potential studies in carrier populations that include both homozygous and heterozygous patients. Additionally, she talked about the appropriate endpoints and assessments needed to fully understand the potential of ALZ-801.